Haspin: a promising target for the design of inhibators as potent anticancers drugs
| dc.contributor.author | AMOUSSOU, NATHALIE GISELE | |
| dc.contributor.author | BIGOT, KOFFI ANDRÉ | |
| dc.contributor.author | Roussakis, CHRISTOS | |
| dc.contributor.author | Robert, Jean-Michel H. | |
| dc.date.accessioned | 2026-06-02T16:06:57Z | |
| dc.date.available | 2026-06-02T16:06:57Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | Protein kinases constitute a large group of enzymes in eukaryotes and have an important role in many cellular processes. Several of these proteins are active kinases, such as haploid germ cell-specific nudear protein kinase (Haspin), an atypical eukaryotic protein kinase that lacks sequence similarity with other eukaryotic protein kinases. Haspin is a serine/threonine kinase that associa tes with chromosome and phosphorylates threonine 3 of histone 3 during mitosis. Haspin overexpression or deletion results in defective mitosis. It has been shown that Haspin inhibitors have potent anti-tumoral effects. Given that the only Haspin substrate is threonine 3 of histone 3, inhibition of Haspin might have fewer adverse QZ effects compared with XXXX. Here, we highlight the chemical structures and actions of currently known Haspin inhibitoTs. | |
| dc.identifier.other | BECDB-7178 | |
| dc.identifier.uri | https://dspace.uac.bj/handle/123456789/6475 | |
| dc.language.iso | fr | |
| dc.relation.ispartof | Drug Dlseovery TodaY | |
| dc.subject | Haspin | |
| dc.subject | inhibators | |
| dc.subject | anticancers | |
| dc.subject | drugs | |
| dc.title | Haspin: a promising target for the design of inhibators as potent anticancers drugs | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- d8416ef28949752a9964343c298ebaf3.pdf
- Size:
- 1.32 MB
- Format:
- Adobe Portable Document Format
